Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

Phase 2

Completed

• Conditions: Birch Pollen Allergy

• Registration Number: NCT00266526
• Lead Sponsor: Allergopharma GmbH & Co. KG

Brief Summary

Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV

Detailed Description

Not available

Study Timeline

• Study Start: 2003-07
• Primary Completion: 2004-07
• Study Completion: 2005-07
• Study First Submitted: 2005-12-16
• Study First Submitted QC: 2005-12-16
• Study First Posted: 2005-12-19
• Status Verified: 2013-03
• Last Update Submitted: 2013-03-01
• Last Update Posted: 2013-03-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Positive RAST result to birch pollen
• Positive Skin Prick Test reaction to birch pollen
• positive nasal provocation test result to birch pollen extract

Exclusion Criteria

• serious chronic diseases
• other relevant seasonal allergies

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Allergopharma GmbH & Co. KG; 🇩🇪 Reinbek, Germany